News & Views
DefiniGEN to Invest in new Stem Cell Lines
Jun 24 2016
Life sciences products provider DefiniGEN has raised £1.5m ($2.29m) in follow-on funding that will support development of new pancreatic and lung stem cells for drug discovery and regenerative medicine. The round was led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, and 24 Haymarket, with key investors Dr Jonathan Milner (Chairman), Providence Investment Company, Parkwalk, and Cambridge Capital Group also participating. This funding follows the closing of £2.28 million ($3.83 million) Series A funding in 2014.
The company’s platform technology OptiDIFF produces cell types that can be used as predictive in vitro models to support the development of safer and more effective treatments for disease ahead of clinical trials. The new funding will also support the company’s business expansion in North America, Europe and Asia Pacific, the funding of new staff and scale-up of production facilities.
Commenting on the announcement, Dr Marcus Yeo, CEO of DefiniGEN said: “In a short space of time, DefiniGEN has undergone rapid development, securing growing sales with global pharma companies. We are delighted to have raised the funds that will allow us to deliver new market-leading products to our customers and assist them in developing therapies for the global healthcare challenges we face today such as diabetes and liver disease.”
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK